Home
NewsNewsMemphasys Felix Qatar IVF orders secure Hamad Medical Corporation as a reference customer, driving robust cartridge demand, accelerating widespread IVF adoption across the MENA region, and establishing crucial clinical credibility for future expansion.
Memphasys Felix Qatar IVF orders entered a commercial execution phase after Hamad Medical Corporation (HMC) began routine clinical purchasing of Felix™ cartridges in Qatar. HMC, the country’s largest public healthcare provider and leading IVF service, is now ordering approximately 100 cartridges per month, supporting close to 1,500 IVF cycles annually and creating a recurring institutional demand profile.
The agreement marks Memphasys’ first large-scale institutional customer in the Middle East and North Africa and follows CE Mark approval, which allows Felix™ to be used immediately across Qatar and other CE-recognised MENA markets. The deployment is being executed under Memphasys’ go-direct commercial strategy with distribution partner International Technical Legacy.
HMC’s projected annual usage of roughly 1,200 cartridges represents almost half of International Technical Legacy’s minimum annual commitment of 2,500 cartridges, significantly de-risking contracted volumes. This single institutional adoption also establishes a high-credibility reference point for Memphasys Felix Qatar IVF orders as the company targets broader uptake across the region’s estimated 350 IVF clinics.
Felix™ is positioned as an alternative to centrifugation-based sperm preparation, which can expose sperm cells to mechanical stress and DNA damage. The system uses a patented bioseparation process combining electrophoresis and size-exclusion membranes to isolate viable sperm with reduced cellular stress, faster laboratory workflows and more standardised results across operators.
Outside of Qatar, Memphasys has also received a follow-on order of 200 cartridges from International Technical Legacy (ITL), representing demand from clinics across the UAE and neighbouring regions. Memphasys is in late-stage commercial discussions with clinics in five other countries, looking to expand into those markets in the short-term.
Egypt will be another focus market for Memphasys expansion, with demand for IVF therapies expected to reach over USD 500 million. To continue supporting growth in the region, Memphasys’ A/Prof Hassan Bakos, Director of Clinical Partnerships and Growth, will undertake his second partner-funded visit to the region. He will be working with HMC to optimise usage, onboard clinics rapidly and meet with clinicians at a large ART conference taking place in Egypt.
Together, the HMC deployment and follow-on regional orders demonstrate that Felix™ is transitioning from evaluation to routine clinical use. The cartridge-based consumable model supports recurring revenue, while institutional adoption provides validation that extends beyond a single customer win.
Wisconsin lawmakers from both parties are proposing bills to reduce IVF treatment costs. Republicans suggest a $5,000 tax credit for expenses, while Democrats want mandatory insurance coverage. With IVF cycles costing $20,000-$30,000 and 170,000 residents facing infertility, both parties seek affordable solutions through different approaches.
The AI-specialized Infertility Center, which is the largest in Asia, is open in Magok, Seoul and has begun its full-scale medical services from November 17 thereby marking the new era when it comes to fertility in the region.
Alife Health secured CE Mark approval for its AI-powered embryo selection tool, Embryo Predict, under EU MDR, expanding its fertility technology presence across Europe.
Simbryo Technologies introduces the Simbryo FX personalized assay, a diagnostic test that measures endometrial fertility to predict embryo implantation success and improve IVF outcomes with more than 90% specificity.
South Korean couples travel abroad for gender-selective IVF procedures, spending dollars in Thailand and Cyprus due to domestic legal restrictions on choosing a baby's sex.
As more families pursue fertility treatments, IVF CRYO urges greater transparency and safety in better Safe Embryos and Eggs Shipping across the U.S.
China sees a rise in advanced maternal age In Vitro Fertilization, driven by BaseCare Medical’s AI undisturbed culture system that improves embryo quality and clinical pregnancy rates, especially with PGT. Localized AI-assisted solutions position BaseCare as a leader in smart, precision reproduction technology for older IVF patients.
